Nivagen Company Profile
What is the competitive landscape for NIVAGEN
NIVAGEN has nine approved drugs.
Drugs and US Patents for Nivagen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nivagen Pharms Inc | EFINACONAZOLE | efinaconazole | SOLUTION;TOPICAL | 211969-001 | Jun 21, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nivagen | SUCCINYLCHOLINE CHLORIDE | succinylcholine chloride | INJECTABLE;INJECTION | 211625-001 | May 19, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nivagen | DECITABINE | decitabine | INJECTABLE;INTRAVENOUS | 212117-001 | Dec 7, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nivagen | REMIFENTANIL HYDROCHLORIDE | remifentanil hydrochloride | INJECTABLE;INJECTION | 215635-003 | Jun 28, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nivagen | REMIFENTANIL HYDROCHLORIDE | remifentanil hydrochloride | INJECTABLE;INJECTION | 215635-002 | Jun 28, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nivagen | TEMOZOLOMIDE | temozolomide | CAPSULE;ORAL | 213328-001 | Nov 23, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

